toxylact: a04ad01 scopolamine

The first professional lActological database in the word

Scopolamine (ATC A04AD01) is an antimuscarinic antiemetic and antispasmodic agent that requires cautious use in lactating patients due to its central anticholinergic effects and excretion into breast milk.medpedia.framar

Overview and ATC classification

Scopolamine is a naturally occurring tropane alkaloid derived from Solanaceae plants, structurally related to atropine and hyoscyamine and mimicking acetylcholine at muscarinic receptors. It is classified in ATC group A04AD01, within “other antiemetics”, under the broader “drugs for functional gastrointestinal disorders and antiemetics”. The drug is available as oral formulations, parenteral solutions and transdermal patches for systemic use.medpedia.framar

Mechanism of action and pharmacology

Scopolamine acts as a competitive antagonist at central and peripheral M1-type muscarinic receptors, inhibiting parasympathetic activity in organs innervated by postganglionic cholinergic nerves. This leads to reduced salivary and respiratory secretions, mydriasis, decreased gastrointestinal motility and antispasmodic effects, with no relevant action on nicotinic receptors. It is extensively metabolised in the liver via phase II conjugation (glucuronides and sulfides), with in vitro data implicating CYP3A subfamily–mediated oxidative demethylation and modulation by grapefruit juice, suggesting CYP3A4 involvement.medpedia.framar

Indications and clinical use

In low doses, scopolamine is indicated for prevention and treatment of postoperative nausea and vomiting and motion sickness (including sea sickness), often via transdermal patch behind the ear. Additional uses include gastrointestinal, biliary and renal colic, adjunctive use in GI radiology and endoscopy, irritable bowel syndrome, and reduction of clozapine‑induced sialorrhea. It may also be used as premedication before surgery to reduce airway secretions and facilitate anaesthesia.medpedia.framar

Contraindications, precautions and toxicity

Scopolamine is contraindicated in hypersensitivity to scopolamine or other belladonna alkaloids and in angle‑closure glaucoma. It must be used with particular caution in patients with open‑angle glaucoma, benign prostatic hyperplasia, seizure or psychosis history, ulcerative colitis, hypertension, hyperthyroidism, Down syndrome, toxin‑mediated diarrhoea, coronary artery disease, tachyarrhythmias, structural brain injury, spastic paralysis in children and conduction disturbances or chronic heart failure. Central nervous system depression, paradoxical bradycardia at low doses, idiosyncratic toxic psychosis (agitation, delirium, hallucinations, paranoid behaviour) and withdrawal phenomena after high‑dose or abrupt discontinuation, especially after patch removal, have been reported.medpedia.framar

Adverse effects and overdose

The most frequent adverse effects are dry mouth, blurred vision and mydriasis. Less common reactions (0.1–1%) include anhidrosis, tachycardia (often followed by bradycardia), urticaria and pruritus, while rare events comprise constipation, urinary retention, hallucinations, agitation, confusion, anxiety and seizures. Reactions of unknown frequency include anaphylactic shock, dyspnoea, rash, erythema and broader hypersensitivity, together with somnolence, dizziness and visual disturbances. Overdose presents with tachycardia, arrhythmias, photophobia, urinary retention, pronounced mucosal dryness, skin flushing, inhibition of GI motility and CNS depression or paradoxical hallucinations, for which physostigmine (a centrally acting cholinergic agent) is an antidote alongside gastric decontamination and supportive care.medpedia.framar

Lactation and infant risk

Scopolamine is excreted into human breast milk, although quantitative human data are lacking. Given its central anticholinergic profile, nursing infants may be at theoretical risk of sedation, feeding difficulties, decreased GI motility and potential cardiorespiratory effects, particularly with maternal use of transdermal systems delivering continuous systemic exposure. The manufacturer advises caution when prescribing scopolamine to breastfeeding women, and short‑term, lowest‑effective dosing with monitoring of the infant for dry mouth, poor suck, unusual drowsiness, irritability or urinary retention is prudent.medpedia.framar

Pharmacokinetics and dosing in lactating patients

After oral administration, only about 2.6% of unchanged scopolamine is recovered in urine, reflecting substantial first‑pass metabolism. With transdermal delivery, less than 10% of the dose (parent drug plus metabolites) appears in urine over 108 hours and under 5% is recovered unchanged, indicating sustained low but continuous systemic levels. Elimination half‑life depends on route: IV, oral and IM routes are similar, whereas subcutaneous application yields a longer half‑life around 213 minutes, and plasma concentrations after patch removal decline log‑linearly with a half‑life of about 9.5 hours. In lactating patients, use of intermittent parenteral doses for single procedures may pose lower cumulative infant exposure than prolonged patch therapy, but either route should be reserved for clear maternal benefit with post‑dose observation of the infant.medpedia.framar

Drug interactions relevant in breastfeeding

Scopolamine interacts with medicines that share anticholinergic properties, increasing the risk of central toxicity, urinary retention and visual disturbances. Additional caution is warranted when combined with opioids, gabapentinoids, benzodiazepines, zolpidem, ethanol, cannabinoids, nicotine and certain diuretics, which may enhance CNS depression or autonomic instability in the mother and indirectly affect milk production and caregiving capacity. Concomitant use with other antiemetics that possess anticholinergic activity (for example dimenhydrinate or related agents) should be minimised or carefully titrated.medpedia.framar

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.